Transdermal Neuroprotective Composition for Traumatic Brain Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for traumatic brain injury (TBI) are inadequate in addressing secondary brain injuries caused by brain swelling, hypoxemia, and hypotension, which often lead to increased morbidity and mortality, and there is a need for more accurate diagnosis and effective prevention of milder TBI cases.
Innovation Solution
A pharmaceutical composition comprising chromium III chloride, magnesium sulfate, thiamine, and other iron-chelating agents is administered transdermally to directly access the central nervous system, reducing neuroinflammatory responses and oxidative stress, thereby preventing cognitive, behavioral, and physical impairments associated with TBI.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transdermal administration is used to directly access the central nervous system, then the effectiveness of treatment is improved, but the ability to cross the blood-brain barrier is worsened (blocked)
Solution Approach 1:
The patent uses transdermal administration as an intermediary route to deliver peptides through the skin and into the bloodstream, bypassing the blood-brain barrier blockage. The peptide composition is formulated for transdermal delivery systems that facilitate penetration through the skin barrier and into the circulatory system, enabling CNS access without direct blood-brain barrier crossing
Solution Approach 2:
The patent replaces the conventional mechanical/intravenous administration system with a transdermal delivery system. This substitution uses topical application and transdermal penetration mechanisms instead of direct injection or oral administration, leveraging the skin's absorptive properties to deliver therapeutic peptides systemically
2Ease of manufacture
If current treatments are used for TBI, then standard care is provided, but secondary brain injuries are not adequately addressed
Solution Approach 1:
The patent applies preliminary protective action by administering peptides that prevent secondary brain injury mechanisms before they fully develop. The treatment targets preemptive protection against neuroinflammation, oxidative stress, and excitotoxicity that occur in the hours following TBI, rather than treating established damage
Solution Approach 2:
The patent changes the therapeutic parameter from standard conventional care to peptide-based neuroprotection. This involves introducing new active ingredients (neuroprotective peptides) that target specific molecular pathways involved in secondary injury, changing the biochemical parameters of treatment rather than relying on conventional supportive care alone
3Measurement precision
If milder TBI cases are diagnosed more accurately, then more patients can be treated, but the complexity of diagnosis increases
Solution Approach 1:
The patent uses biomarker detection as a simplified copy or proxy for complex neurological assessment. By measuring specific biochemical markers in blood or other accessible fluids that indicate TBI presence and severity, the system provides accurate diagnosis without requiring complex neurological examinations or advanced imaging for all patients
Data Source
AI summary
The present invention provides methods for treating an inflammatory brain disease and for treating a traumatic brain injury in a human having an inflammatory component applying transdermal pharmaceutical compositions comprising chromium, magnesium, and thiamine as active ingredient compounds that act as neuroprotective iron chelators and brain glucose-uptake enhancement that are suitable for the treatment of traumatic brain injury. The invention further relates to methods of delivering the pharmaceutical compositions that target the brain and/or central nervous system certain novel iron chelators of the type described in the specification.